CVS Health Corporation $CVS Stock Position Lowered by Burney Co.

Burney Co. lowered its holdings in CVS Health Corporation (NYSE:CVS) by 30.2% in the first quarter, Holdings Channel.com reports. The firm owned 65,241 shares of the pharmacy operator’s stock after selling 28,272 shares during the period. Burney Co.’s holdings in CVS Health were worth $4,686,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in CVS. Caitong International Asset Management Co. Ltd lifted its position in CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after buying an additional 281 shares in the last quarter. Swiss RE Ltd. bought a new position in shares of CVS Health during the 4th quarter valued at $26,000. Sankala Group LLC acquired a new position in CVS Health during the fourth quarter worth $28,000. Global Trust Asset Management LLC lifted its position in shares of CVS Health by 344.8% in the first quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock worth $28,000 after buying an additional 300 shares during the last quarter. Finally, Mcguire Capital Advisors Inc. bought a new position in shares of CVS Health in the 4th quarter valued at approximately $28,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of CVS Health in a research note on Friday, May 8th. UBS Group increased their target price on CVS Health from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Monday, June 8th. Deutsche Bank Aktiengesellschaft raised their target price on CVS Health from $88.00 to $92.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Mizuho upped their price target on CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Monday, June 8th. Finally, Barclays increased their price objective on CVS Health from $101.00 to $106.00 and gave the company an “overweight” rating in a research report on Tuesday, May 26th. Twenty-one research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, CVS Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $102.60.

CVS Health Stock Down 2.5%

NYSE CVS opened at $102.13 on Tuesday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The firm has a 50-day simple moving average of $94.56 and a 200 day simple moving average of $83.31. CVS Health Corporation has a twelve month low of $58.50 and a twelve month high of $106.15. The stock has a market cap of $130.31 billion, a PE ratio of 44.99, a PEG ratio of 1.03 and a beta of 0.61.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, research analysts forecast that CVS Health Corporation will post 7.44 EPS for the current year.

Insider Buying and Selling

In other CVS Health news, Director Larry Robbins sold 370,462 shares of the business’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the sale, the director owned 4,824,799 shares of the company’s stock, valued at $450,877,466.55. The trade was a 7.13% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This represents a 87.28% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is currently owned by company insiders.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is being promoted as a momentum stock and a potential pick for investors looking for names with strong technical or sentiment-driven upside. Are You Looking for a Top Momentum Pick? Why CVS Health (CVS) is a Great Choice
• Positive Sentiment: Analyst-style commentary argued that CVS is a healthcare outlier with a credible turnaround story, citing a Q1 beat-and-raise, expected margin expansion in 2026, and improving business execution. CVS Health: The Surprising Healthcare Outlier
• Positive Sentiment: Jim Cramer’s favorable view on CVS has also been cited as a catalyst, reinforcing investor confidence in the stock’s outlook. CVS Health Corporation (CVS) Shares Up Significantly After Jim Cramer Said He Was Looking For A Good Year
• Neutral Sentiment: CVS announced it will hold its second-quarter 2026 earnings call on August 5, which keeps investors focused on upcoming results but does not change fundamentals by itself. CVS Health to hold second quarter 2026 earnings conference call
• Neutral Sentiment: The CVS Health Foundation’s $1 million donation to Hartford nonprofits supports community health efforts and is positive for reputation, but it is unlikely to move the stock materially on its own. CVS Health Foundation Invests $1 Million in Hartford Nonprofits Tackling Community Health Needs
• Negative Sentiment: CVS-branded medicated wipes were recalled due to a child poisoning risk, which could create a small reputational headwind for the company and its retail business. Over 75,000 CVS medicated wipes recalled nationwide due to severe child poisoning risk
• Negative Sentiment: Another recall-related report flagged CVS medicated wipes over child safety concerns, adding to short-term product-safety pressure. CVS Health medicated wipes recalled over child safety concerns

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.